News 2013
October 2013

8th Hanseatic India Colloqium
"Transnational Cooperation in Drug Development and Clinical Research"

October 25, 2013, 9:30 h to 18:00 h
Conference Room Allianz Germany AG, Sprinkenhof, 7th Floor, Burchardstr. 8, 20095 Hamburg

The 8th Hanseatic India Colloqium was an interesting, informative and very well attended meeting. We had several top Indian Pharmaceutical and biotech companies attending the event and we learnt about the excellent research and development work going on in India especially in the area of cost effective generics production. At the same time, several Hamburg based pharma and biotech companies presented data on how they have progressed in research and development work and outlined some of the avenues for effective Indo-German collaboration especially to develop innovative therapy at an affordable cost.

Pictures

  Program/Presentations
  Opening Session
   
  Word of Greetings by Stephan Matz, Director International Department, HWF Hamburg Business Development Corporation, Hamburg, Germany
   
  Welcome Address by Dr. Hinrich Habeck, Managing Director, Norgenta North German Life Science Agency, Hamburg, Germany
   
  Opening Address by H. E. Dr. Vidhu P. Nair, Acting Consul General of India, Hamburg, Germany
   
  Session I
Chair: Dr. Amal Mukhopadhyay, Founder and Director, ELGA Biotech, Hamburg, Germany
   
  Feeding the drug discovery pipeline with innovative ideas from academia: A model for Indo-German Collaboration in R & D
Dr. Björn Windshügel, Head of Bioinformatics, European Screening Port GmbH, Hamburg, Germany
   
  Generics in healthcare in a global perspective: Opportunities offered by India
Vimalendu K. Singh, Chief Executive Global Generics, RPG Life Sciences Ltd., Mumbai, India
   
  Clinical Research: A fundamental component of drug discovery
Prof. Dr. Rainer Böger, Managing Director, Clinical Trial Center North, Hamburg, Germany
   
  Session II
Chair: Dr. Hinrich Habeck, Managing Director, Norgenta North German Life Science Agency, Hamburg, Germany
   
  Generic drug development, Indian scenario
Dr. Vijay K. Shastri, Technical Director, Murli Krishna Pharma Pvt. Ltd, Pune, India
   
  API manufacturing in India: Opportunities and challenges especially with the issue of quality control
Dr. Antony Raj Gomas, Sr. Vice President – Quality, Mylan Laboratories Ltd., Hyderabad, India
   
  Legal challenges for transnational co-operations in drug development and clinical research
Dr. Stefanie Greifeneder, Partner Munich, Field Fisher Waterhouse LLP, Munich, Germany
   
  Session III
Chair: Dr. Antony Raj Gomas, Sr. Vice President – Quality, Mylan Laboratories Ltd., Hyderabad, India
   
  50 Years of Generic Experience - Exploiting Synergies in India
Dr. Harm Peters, Managing Director, AET Biotechnologie GmbH, Hamburg, Germany
   
  Scaling Business to the next level, Pharmaceutical Industry
Satya R. Vadlamani, Chief Managing Director, Murli Krishna Pharma Pvt. Ltd, Pune, India
   
  Richter-Helm: Global Partner for Biotechnology and Biosimilars
Federico Pollano, Managing Director, Richter-Helm Biotec GmbH & Co KG, Hamburg, Germany
   
  Adding a New Dimension: Extending Business from Small Molecules To Biologics
Dr. Wolfram Altenhofen, Vice President Business Development, AET Biotechnologie GmbH, Hamburg, Germany
   
  Conclusion of the Event and Networking
 

News Archive 2012

News Archive 2011

News Archive 2010

News Archive 2009

News Archive 2008

   
 
   
© 2007-2017 ELGA BIOTECH All rights reserved